Gyroscope Capital Management Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $5.22M | Buy |
34,989
+2,825
| +9% | +$415K | 1.2% | 28 |
|
|
2023
Q2 | $4.33M | Buy |
32,164
+167
| +0.5% | +$24.5K | 1% | 34 |
|
|
2023
Q1 | $5.1M | Buy |
31,997
+86
| +0.3% | +$13.1K | 1.3% | 27 |
|
|
2022
Q4 | $5.16M | Buy |
+31,911
| New | +$4.89M | 1.56% | 26 |
|
|
2022
Q3 | – | Sell |
-20,000
| Closed | -$3.06M | – | 116 |
|
|
2022
Q2 | $3.06M | Hold |
20,000
| – | – | 1.05% | 33 |
|
|
2022
Q1 | $3.24M | Sell |
20,000
-1,900
| -9% | -$276K | 1.11% | 31 |
|
|
2021
Q4 | $2.96M | Hold |
21,900
| – | – | 1.04% | 30 |
|
|
2021
Q3 | $2.36M | Hold |
21,900
| – | – | 0.89% | 30 |
|
|
2021
Q2 | $2.47M | Hold |
21,900
| – | – | 0.87% | 30 |
|
|
2021
Q1 | $2.37M | Sell |
21,900
-1,135
| -5% | -$121K | 0.95% | 28 |
|
|
2020
Q4 | $2.47M | Buy |
23,035
+3,432
| +18% | +$330K | 1.06% | 28 |
|
|
2020
Q3 | $1.72M | Sell |
19,603
-5,371
| -22% | -$506K | 0.78% | 31 |
|
|
2020
Q2 | $2.45M | Buy |
24,974
+5,974
| +31% | +$526K | 1.11% | 26 |
|
|
2020
Q1 | $1.45M | Hold |
19,000
| – | – | 0.68% | 31 |
|
|
2019
Q4 | $1.68M | Sell |
19,000
-473
| -2% | -$39.3K | 0.61% | 33 |
|
|
2019
Q3 | $1.44M | Hold |
19,473
| – | – | 0.57% | 36 |
|
|
2019
Q2 | $1.42M | Hold |
19,473
| – | – | 0.54% | 39 |
|
|
2019
Q1 | $1.58M | Sell |
19,473
-11,450
| -37% | -$937K | 0.6% | 34 |
|
|
2018
Q4 | $2.85M | Buy |
+30,923
| New | +$2.72M | 1.09% | 28 |
|
|
2018
Q3 | – | Sell |
-68,271
| Closed | -$6.33M | – | 114 |
|
|
2018
Q2 | $6.33M | Buy |
68,271
+3,616
| +6% | +$353K | 2.8% | 21 |
|
|
2018
Q1 | $6.12M | Sell |
64,655
-2,622
| -4% | -$288K | 2.91% | 20 |
|
|
2017
Q4 | $6.51M | Buy |
67,277
+877
| +1% | +$82.7K | 2.97% | 12 |
|
|
2017
Q3 | $5.9M | Sell |
66,400
-18,066
| -21% | -$1.38M | 2.98% | 10 |
|
|
2017
Q2 | $6.13M | Sell |
84,466
-5,359
| -6% | -$360K | 3.06% | 2 |
|
|
2017
Q1 | $5.85M | Buy |
89,825
+19,640
| +28% | +$1.23M | 3.52% | 1 |
|
|
2016
Q4 | $4.39M | Buy |
70,185
+3,926
| +6% | +$240K | 2.94% | 17 |
|
|
2016
Q3 | $4.18M | Buy |
66,259
+3,389
| +5% | +$219K | 3.12% | 11 |
|
|
2016
Q2 | $3.89M | Buy |
62,870
+631
| +1% | +$38.4K | 3.17% | 12 |
|
|
2016
Q1 | $3.56M | Buy |
62,239
+2,236
| +4% | +$125K | 2.73% | 19 |
|
|
2015
Q4 | $3.56M | Buy |
60,003
+260
| +0.4% | +$15K | 2.79% | 20 |
|
|
2015
Q3 | $3.25M | Buy |
59,743
+3,565
| +6% | +$232K | 2.77% | 19 |
|
|
2015
Q2 | $3.77M | Sell |
56,178
-1,824
| -3% | -$119K | 3.09% | 7 |
|
|
2015
Q1 | $3.4M | Buy |
+58,002
| New | +$3.5M | 2.8% | 20 |
|
Other funds holding ABBV
Gyroscope Capital Management Group's ABBV Position: Q3 2023 in Review
Gyroscope Capital Management Group increased its AbbVie (ABBV) stake by 8.8% in Q3 2023, buying an estimated $415K and bringing the position to 34,989 shares worth $5.22M. The position accounts for 1.2% of the portfolio, ranked #28.
Gyroscope Capital Management Group first reported a position in ABBV in Q1 2015 and has held it in 33 quarters since. The position peaked at $6.51M in Q4 2017. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.
- Gyroscope Capital Management Group held 34,989 shares of AbbVie worth $5.22M as of Q3 2023.
- Gyroscope Capital Management Group bought 2,825 AbbVie shares in Q3 2023, an estimated $415K.
- AbbVie made up 1.2% of Gyroscope Capital Management Group's portfolio in Q3 2023, its #28 holding.
- Gyroscope Capital Management Group first reported a position in AbbVie in Q1 2015 and has held it in 33 quarters since.
- Gyroscope Capital Management Group's AbbVie position peaked at $6.51M in Q4 2017.
- 3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.
Based on Gyroscope Capital Management Group's 13F filing for Q3 2023, filed 13 Nov 2023.